Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Denton

Showing results (411-420 of 607) with videos related to

Pageof 61
Sort By:
Arthritis and Rheumatism|April 3, 2008
Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse modelRachel K Hoyles, Korsa Khan, Xu Shiwen, et al.
European Heart Journal. Cardiovascular Imaging|August 19, 2024
Prognostic utility of exercise cardiovascular magnetic resonance in patients with systemic sclerosis-associated pulmonary arterial hypertensionJames T Brown, Ruta Virsinskaite, Tushar Kotecha, et al.
Journal of Scleroderma and Related Disorders|June 24, 2024
Attitudes and barriers to pulmonary arterial hypertension screening in systemic sclerosis patients: A survey of UK-based rheumatologistsMaría Paula Álvarez-Hernández, Yannick Allanore, Ivo Andrade, et al.
The Journal of Rheumatology|May 16, 2021
Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis SubsetsTatiana Nevskaya, Janet E Pope, Matthew A Turk, et al.
European Neurology|January 31, 2008
Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexateG J D Hengstman, J L De Bleecker, E Feist, et al.
Annals of the Rheumatic Diseases|June 5, 2026
Pulmonary arterial hypertension susceptibility and mortality among patients with systemic sclerosis with the DNASE1L3 rs35677470 (Arg206Cys) variantBrian Skaug, Stefano Rodolfi, Christopher P Denton, et al.
Annals of the Rheumatic Diseases|December 7, 2007
Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseasesC P Denton, J E Pope, H-H Peter, et al.
Rheumatology (Oxford, England)|May 22, 2026
The clinical utility of telangiectasia quantification as markers of vascular disease progression in systemic sclerosisMatthew Wells, Theresa Smith, Robyn T Domsic, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 5, 2015
Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary HypertensionK M Antoniou, G A Margaritopoulos, N S Goh, et al.
Arthritis and Rheumatism|June 3, 2008
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysisOliver Distler, Frank Behrens, David Pittrow, et al.
Pageof 61

Showing results (411-420 of 607) with videos related to

Sort By:
Pageof 61
Arthritis and Rheumatism|April 3, 2008
Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse modelRachel K Hoyles, Korsa Khan, Xu Shiwen, et al.
European Heart Journal. Cardiovascular Imaging|August 19, 2024
Prognostic utility of exercise cardiovascular magnetic resonance in patients with systemic sclerosis-associated pulmonary arterial hypertensionJames T Brown, Ruta Virsinskaite, Tushar Kotecha, et al.
Journal of Scleroderma and Related Disorders|June 24, 2024
Attitudes and barriers to pulmonary arterial hypertension screening in systemic sclerosis patients: A survey of UK-based rheumatologistsMaría Paula Álvarez-Hernández, Yannick Allanore, Ivo Andrade, et al.
The Journal of Rheumatology|May 16, 2021
Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis SubsetsTatiana Nevskaya, Janet E Pope, Matthew A Turk, et al.
European Neurology|January 31, 2008
Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexateG J D Hengstman, J L De Bleecker, E Feist, et al.
Annals of the Rheumatic Diseases|June 5, 2026
Pulmonary arterial hypertension susceptibility and mortality among patients with systemic sclerosis with the DNASE1L3 rs35677470 (Arg206Cys) variantBrian Skaug, Stefano Rodolfi, Christopher P Denton, et al.
Annals of the Rheumatic Diseases|December 7, 2007
Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseasesC P Denton, J E Pope, H-H Peter, et al.
Rheumatology (Oxford, England)|May 22, 2026
The clinical utility of telangiectasia quantification as markers of vascular disease progression in systemic sclerosisMatthew Wells, Theresa Smith, Robyn T Domsic, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 5, 2015
Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary HypertensionK M Antoniou, G A Margaritopoulos, N S Goh, et al.
Arthritis and Rheumatism|June 3, 2008
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysisOliver Distler, Frank Behrens, David Pittrow, et al.
Pageof 61